论文部分内容阅读
目的建立测定朝藿定C在健康人血浆和犬血浆中蛋白结合率的方法。方法采用平衡透析法结合HPLC法对朝藿定C与健康人血浆和犬血浆的蛋白结合率进行测定。采用Waters C18柱,柱温为25℃,流动相为乙腈-水(30∶70),流速为1 mL/min,检测波长为269 nm。结果朝藿定C在不同介质中的精密度和回收率均较好,与人血浆在100、50、25 mg/L质量浓度下的血浆蛋白结合率分别为(75.6±1.6)%、(72.5±1.3)%、(76.5±0.8)%;与犬血浆在100、50、25 mg/L质量浓度下的血浆蛋白结合率分别为(70.0±1.7)%、(72.4±2.2)%、(74.0±2.0)%。结论体外朝藿定C与人血浆和犬血浆蛋白结合率较高,且与血药无明显的浓度依赖性。
Objective To establish a method for determining the protein binding of Buyi C in healthy human plasma and dog plasma. Methods The equilibrium binding assay (HPLC) was used to determine the protein binding of epimedin C to plasma and dog plasma. A Waters C18 column was used at 25 ℃. The mobile phase consisted of acetonitrile-water (30:70), the flow rate was 1 mL / min and the detection wavelength was 269 nm. Results The determination of epimedin C in different media showed good precision and recovery, and the plasma protein binding rates with human plasma at concentrations of 100, 50 and 25 mg / L were (75.6 ± 1.6)% and (72.5 ± 1.3%, and (76.5 ± 0.8)%, respectively. The plasma protein binding rates to the plasma of dogs at the concentrations of 100, 50 and 25 mg / L were (70.0 ± 1.7)%, (72.4 ± 2.2)% and ± 2.0)%. Conclusion Epimedin C in vitro with high plasma and dog plasma protein binding rate, and with no significant concentration-dependent plasma.